| CHRS Stock | | | USD 1.22 0.04 3.17% |
Chairman
Mr. Dennis M. Lanfear is Chairman of the Board, President, Chief Executive Officer of the Coherus BioSciences, Inc. He is our cofounder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since our inception in September 2010. Mr. Lanfear previously was President of InteKrin Therapeutics Inc., a biopharmaceutical company, from 2005 to May 2010. Prior to that, Mr. Lanfear served in various senior leadership roles at Amgen Inc., a biopharmaceutical company from 1986 to 1999. While at Amgen, Mr. Lanfear had key leadership positions in the Process Development department, which under his management became an area of key strategic advantage for Amgen. Mr. Lanfear has also held senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins and directed efforts from preclinical studies to Phase 3 clinical trials at Amgen since 2016.
| Age | 69 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 |
| Phone | 650 649 3530 |
| Web | https://www.coherus.com |
Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles. We believe Mr. Lanfear is qualified to serve on our Board of Directors because of his background and various leadership roles in the biopharmaceutical field.
Coherus BioSciences Management Efficiency
The company has return on total asset
(ROA) of
(0.1403) % which means that it has lost $0.1403 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Equity is likely to gain to 1.97 in 2024, whereas
Return On Tangible Assets are likely to drop
(0.45) in 2024. At this time, Coherus BioSciences'
Non Current Assets Total are comparatively stable compared to the past year.
Non Currrent Assets Other is likely to gain to about 74.8
M in 2024, whereas
Total Current Assets are likely to drop slightly above 311.1
M in 2024.
Coherus BioSciences currently holds 480.84
M in liabilities. Coherus BioSciences has a current ratio of 3.11, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Coherus BioSciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | CHAIRMAN Age |
| Sean DPHIL | CytomX Therapeutics | 57 |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people. Coherus BioSciences (CHRS) is traded on NASDAQ Exchange in USA. It is located in 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 and employs 235 people. Coherus BioSciences is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Coherus BioSciences Leadership Team
Elected by the shareholders, the Coherus BioSciences' board of directors comprises two types of representatives: Coherus BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coherus. The board's role is to monitor Coherus BioSciences' management team and ensure that shareholders' interests are well served. Coherus BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coherus BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vladimir Vexler, Chief Scientific Officer | |
| Bryan Mcmichael, Principal Accounting | |
| Dennis Lanfear, Chairman, CEO and Pres | |
| Michael Chen, Senior Trade | |
| Theresa Lavallee, Chief Board | |
| MRCP MD, Chief Officer | |
| Rebecca Sunshine, Chief Officer | |
| Scott Saywell, Executive Development | |
| Jodi Sievers, Vice Communications | |
| Karen Kotz, Ex Accounts | |
| Jami Taylor, Vice Relations | |
| Christopher Slavinsky, Chief Officer | |
| Cheston Turbyfill, Vice Communications | |
| Andy Rittenberg, Executive Counsel | |
| McDavid Stilwell, Chief Officer | |
| Paul Reider, Chief Officer | |
| Richard Hameister, Chief Officer | |
Coherus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coherus BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to
measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to
predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.